Compare Schwab US Dividend Equity ETF (SCHD) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Schwab US Dividend Equity ETF vs BIO-TECHNE Corp — how do they compare? Schwab US Dividend Equity ETF trades at $33.04 (market cap $110.56B), while BIO-TECHNE Corp trades at $72.46 (market cap $11.36B). The key difference: Schwab US Dividend Equity ETF is far larger — about 9.7× BIO-TECHNE Corp's market cap, and BIO-TECHNE Corp pays a 0.44% dividend while Schwab US Dividend Equity ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Schwab US Dividend Equity ETF for 62 Days and BIO-TECHNE Corp for 64 Days on average.
| SCHD | TECH | |
|---|---|---|
Market Cap | $110.56B | $11.36B |
Volume | 23,539,168 | 5,390,331 |
Sector | Broad Market / Factor | Health |
52-Week High | $35.21 | $72.61 |
52-Week Low | $26.44 | $43.31 |
Typical Hold Time | 62 Days | 64 Days |
Enterprise Value | — | $11.39B |
Dividend Yield | — | 0.44% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SCHD trades at $33.15, up 1.53% today, with a bullish technical signal despite mixed moving averages. The ETF has outperformed the S&P 500 by nearly 10 percentage points in 2026, with recent dividend growth attracting income-focused investors. Technical indicators show neutral oscillators but strong trend momentum with ADX readings above 60.
SCHD offers dividend growth potential with lower fees than competitors, though its defensive tilt may lag in growth markets. Key risks include interest rate sensitivity and methodology constraints that excluded high-performing stocks like Broadcom. The current pullback from August highs presents a potential entry point for long-term dividend investors.
TECH trades at $72.45, near its 52-week high of $72.70 (Defense World, 2026-09-28), with a slight 0.11% decline over 24 hours. The stock shows a bullish technical signal, supported by moving averages, while fundamentals reveal a high P/E of 62.46 and net income margin of 14.97% for 2025. Recent news highlights shareholder approval of its acquisition by Merck KGaA at $73.00 per share (PRNewsWire, 2026-09-23), a key catalyst for near-term price action.
The outlook is mixed: the acquisition offers upside to the current price, but elevated valuation ratios pose risks if earnings growth falters. Analyst consensus is divided with 46% buy ratings, and net income volatility from 2022-2025 signals execution challenges. Investors should weigh the acquisition premium against fundamental sustainability in a competitive life sciences tools sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Schwab US Dividend Equity ETF
SCHD is an ETF that tracks the Dow Jones U.S. Dividend 100 Index. It selects high-quality companies with a consistent track record of paying dividends, focusing on financial strength metrics like cash flow to total debt and return on equity, and excluding REITs. The fund aims to provide both income and capital appreciation, making it a popular choice for long-term, dividend-focused investors.
Read more on SCHD →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
